Phase I study of CAR-T cells with PD-1 and TCR disruption in mesothelin-positive solid tumors.
Wang Z, Li N, Feng K, Chen M, Zhang Y, Liu Y, Yang Q, Nie J, Tang N, Zhang X, Cheng C, Shen L, He J, Ye X, Cao W, Wang H, Han W.
Wang Z, et al. Among authors: yang q.
Cell Mol Immunol. 2021 Sep;18(9):2188-2198. doi: 10.1038/s41423-021-00749-x. Epub 2021 Aug 11.
Cell Mol Immunol. 2021.
PMID: 34381179
Free PMC article.
Clinical Trial.